PerkinElmer Q1 revenues edge up, profit edges down

By The Science Advisory Board staff writers

May 8, 2020 -- In financial results for the first quarter, PerkinElmer saw revenues grow slightly, but net income slipped.

For the period, PerkinElmer recorded revenues of $652.4 million, up 1% compared to revenue of $648.7 million in the first quarter of 2019. The company's net income fell slightly, to $33.7 million, compared with $35.4 million in the corresponding quarter the year before.

In the company's diagnostics business, revenue was $254 million, compared to $259.9 million in the first quarter of 2019. Operating income from continuing operations in the business was $29.6 million, versus $31.5 million the same period the year before.

PerkinElmer executives said the company delivered "a very good quarter" despite macroeconomic uncertainty. At the same time, in releasing the financial results, PerkinElmer withdrew its previously issued financial guidance for the rest of the year.

The company also announced that its SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) for immunoglobulin G (IgG) antibodies has been granted emergency use authorization by the U.S. Food and Drug Administration (FDA). The test is ready for use by labs that are CLIA-certified to perform high complexity testing, the company said.


Copyright © 2020 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.